GLP‑1 Weight‑Loss Drugs Trigger “Ozempic Feet” Foot Changes

Rapid weight loss caused by GLP‑1 receptor agonists such as Ozempic, Wegovy, Mounjaro and Zepbound can lead to loss of the protective fat pads and muscle in the feet. Patients report loose, saggy skin, prominent veins and tendons, a “walking on pebbles” sensation, heel pain and the need to change shoe size or style. The diminished cushioning heightens the risk of blisters, calluses, ulcers and serious wounds, particularly for people with diabetes. Podiatrists in the United States, Germany, Belgium and the Netherlands have highlighted the phenomenon, which they label “Ozempic feet,” even though it is not listed among official drug side effects. Experts advise monitoring foot health, increasing protein intake, engaging in resistance training and using properly fitting footwear to mitigate the problem. The issue reflects a broader pattern of tissue‑adaptation lag when fat loss outpaces skin and muscular adjustment during fast weight reduction.